추천 제품
Grade
pharmaceutical primary standard
API family
dextranomer
제조업체/상표
EDQM
응용 분야
pharmaceutical (small molecule)
형식
neat
저장 온도
2-8°C
일반 설명
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
애플리케이션
Dextranomer EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
포장
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
기타 정보
Sales restrictions may apply.
가장 최신 버전 중 하나를 선택하세요:
Aaron P Bayne et al.
Journal of endourology, 24(6), 1013-1016 (2010-04-10)
The injection of dextranomer/hyaluronic acid (DHA) has become an accepted treatment for children with vesicoureteral reflux (VUR). Complete ureteral duplication has been considered by some practitioners as counterindication for its use. We reviewed the Texas Children's Hospital (TCH) records for
Abdol-Mohammad Kajbafzadeh et al.
Journal of endourology, 26(4), 318-324 (2011-11-09)
To present the results of our experience with combined endoureterotomy and endoscopic injection of dextranomer/hyaluronic acid (Deflux) for the treatment of primary obstructive refluxing megaureter (PORM). Eighteen children (12 female, 6 male; mean age-14 months) with 20 PORM units underwent concomitant
Jonathan F Kalisvaart et al.
Journal of pediatric urology, 8(4), 359-365 (2011-08-09)
Follow-up of patients undergoing dextranomer/hyaluronic acid injection for vesico-ureteral reflux (VUR) is controversial. The purpose of our study was to test the hypothesis that patients undergoing the double hydrodistention-implantation technique (Double HIT) have a higher clinical and radiographic success rate.
Oliver Schwandner et al.
Surgical innovation, 18(2), 130-135 (2011-01-20)
The aim of this prospective study was to analyze safety and functional outcome of transanal submucosal injection of dextranomer hyaluronic acid ("bulking agents therapy") in patients with passive fecal incontinence. All patients who underwent transanal injection therapy were prospectively enrolled
Editorial comment.
Anthony A Caldamone
The Journal of urology, 188(1), 261-261 (2012-05-19)
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.